Clinical trials: Neuroectodermal Tumors, Primitive
Relapsed Neuroblastoma
DNA Vaccination Against Neuroblastoma
This is pilot open-label study to evaluate the safety and immunogenicity of a DNA vaccine strategy in relapsed neuroblastoma patients following chemotherapy and HSC transplantation.
- Trial name
- NCT04049864
- Testing
- DNA vaccine, Salmonella oral vaccine, Lenalidomide
- Where
- Belarus
- Volunteers
- 12 people
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Refractory Cancer, Refractory Neoplasm
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor
- Trial name
- NCT04239092
- Testing
- 9-ING-41, Irinotecan, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Actuate Therapeutics Inc.
Neuroblastoma
Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00002634
- Testing
- filgrastim, monoclonal antibody 3F8, cisplatin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Medulloblastoma, Childhood, Cerebral Primitive Neuroectodermal Tumor
Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma
The Register is based on the study HIT 2000 that recruited patients until 31.12.2011. All german patients with intracranial medulloblastoma, CNS-PNET, ependymoma can be included in the register.
- Conditions
- Medulloblastoma, Childhood, Cerebral Primitive Neuroectodermal Tumor, Ependymoma
- Trial name
- NCT02238899
- Where
- Germany
- Volunteers
- 354 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Bladder Cancer, Brain and Central Nervous System Tumors
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Esophageal Cancer, Intraocular Melanoma
- Trial name
- NCT00757614
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 14,000 people
- Sponsor
- Cancer Research UK
Ewing Family of Tumors, Melanoma
Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody
Hu14.18K322A is a monoclonal antibody developed at St. Jude Children's Research Hospital (SJCRH) that is made to bind to cancer cells that have a molecule called GD2 on their surface.
- Conditions
- Ewing Family of Tumors, Melanoma, Neuroblastoma, Osteosarcoma
- Trial name
- NCT02159443
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- St. Jude Children's Research Hospital
Neuroblastoma, Recurrent, Refractory
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, preliminary efficacy, pharmacokinetics of universal T-cells engineered with chimeric natural killer…
- Trial name
- NCT06751134
- Testing
- Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Nanjing Children's Hospital
Neuroblastoma, Neoplasm, Residual
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
The purpose of this study is to evaluate safety of the triple COG schema with the monoclonal antibody Dinutuximab + cytokines (GM-CSF and IL2) and isotretinoin (13-cis-retinoic acid, or RA) in patients with high-risk…
- Conditions
- Neuroblastoma, Neoplasm, Residual, Effects of Immunotherapy
- Trial name
- NCT02169609
- Testing
- Dinutuximab. Immunotherapy
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Fundació Sant Joan de Déu
Congenital Hyperinsulinism, Neuroblastoma
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
Single centre prospective cohort phase III study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients with congenital hyperinsulinism 2. Pediatric patients with neuroblastoma 3.
- Conditions
- Congenital Hyperinsulinism, Neuroblastoma, Neuroendocrine Tumors, Parkinson Disease
- Trial name
- NCT03042416
- Testing
- 18F-DOPA
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- University of Alberta
Neuroblastoma
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00017368
- Testing
- filgrastim, sargramostim, carboplatin
- Where
- 9 sites in United States, Australia
- Volunteers
- 42 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
This Phase One pediatric trial seeks to take advantage of the susceptibility of neuroblastoma to proteasome inhibitors, proven in vitro, along with the proven in vitro synergy of bortezomib with irinotecan and the successful…
- Trial name
- NCT00644696
- Testing
- Irinotecan and Bortezomib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body.
- Conditions
- Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung
- Trial name
- NCT02306161
- Testing
- Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride
- Where
- 314 sites in United States, Canada and 1 more
- Volunteers
- 312 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Brain Tumors, Supratentorial PNETs
Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
The purpose of this study is to improve overall survival while maintaining a good quality of life in pediatric patients with refractory or recurrent brain tumors (medulloblastomas, supratentorial PNETs, ependymomas WHO grade II…
- Conditions
- Recurrent Brain Tumors, Supratentorial PNETs, Medulloblastomas, Ependymomas
- Trial name
- HIT-REZ-2005 (NCT00749723)
- Testing
- carboplatin, etoposide, temozolomide
- Where
- 54 sites in Germany
- Volunteers
- 174 people
- Sponsor
- University Hospital, Bonn
Ependymoma, Brainstem Glioma
A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas
Background: Children with brain tumors often have magnetic resonance imaging (MRI) scans to see if the tumor has responded to therapy or to see if the tumor has grown.
- Conditions
- Ependymoma, Brainstem Glioma, Astrocytoma, Glioblastoma Multiforme
- Trial name
- NCT01117155
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
This study will investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic pancreatic neuroendocrine tumors (PNETs) or or…
- Trial name
- GI-NETorPNET (NCT02132468)
- Testing
- fosbretabulin tromethamine
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mateon Therapeutics
Neuroblastoma, Medulloblastoma
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
The purpose of this research study is to evaluate a new investigational drug (TPI 287) for neuroblastoma and medulloblastoma both alone and in combination with temozolomide (a currently approved drug).
- Conditions
- Neuroblastoma, Medulloblastoma, Relapse
- Trial name
- NCT00867568
- Testing
- TPI 287
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Giselle Sholler
Lymphoma, Prostate Cancer
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00562380
- Testing
- ganitumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Amgen
Neuroblastoma
Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276679
- Testing
- temozolomide
- Where
- 22 sites in France, Ireland and 1 more
- Sponsor
- Children's Cancer and Leukaemia Group
Childhood CNS Primitive Neuroectodermal Tumor
Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors
RATIONALE: Current therapies for children with primitive neuroectodermal tumors that have not responded to standard therapy provide very limited benefit to the patient.
- Trial name
- PNET (NCT00003460)
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Burzynski Research Institute
Neuroblastoma
Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma
In this trial, monoclonal anti-Disialoganglioside GD2 (GD2) antibody ch14.18/CHO will be assessed for the treatment of patients with relapsed or refractory neuroblastoma.
- Trial name
- NCT02743429
- Testing
- dinutuximab beta
- Where
- 2 sites in Austria, Germany
- Volunteers
- 40 people
- Sponsor
- University Medicine Greifswald
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.